SERENTRIX, LLC

Medtech · Still private

Non-opioid topical formulation targeting TRPV1 and cutaneous pain receptors for burn pain management

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Medtech
Total capital
$732K
Federal grants
$732K
3 awards · 2024–2025
Rank in peer group#6 of 28
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
1 pending · first 2019
Rank in peer group#5 of 28

Capital timeline

20242025FEDERAL ↑EQUITY ↓Cumulative $732K$341K$384K$7K
20242025FEDERAL ↑EQUITY ↓Cumulative $732K$341K$384K$7K

Latest events

  • Federal grantHealth and Human S · Phase I · Topical treatment for burn pain by blocking cutaneous pain receptors.$7K
  • Federal grantHealth and Human S · Phase I · Validating SER-014, a TRPV1 antagonist, to treat endometriosis$384K
  • Federal grantHealth and Human S · Phase I · Topical treatment for burn pain by blocking cutaneous pain receptors.$341K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 28 peers

Line = median

Medtech · Molecule

  • Federal grants#6 · top 21%
  • Granted patents#5 · top 18%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 1 granted of 2

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .